[Translation] An open-label, multicenter, phase I/Ib dose-finding and expansion study evaluating HRO761 alone and in combination in patients with microsatellite instability-high or mismatch repair-deficient advanced solid tumors

本研究的目的是确定HRO761单药（s.a.）或与抗PD-1抗体替雷利珠单抗或拓扑异构酶抑制剂伊立替康联合用药的安全性、耐受性、药代动力学（PK）、药效学（PD）和抗肿瘤活性。剂量探索部分的主要目的是确定安全、可耐受的剂量和给药方案，并确定HRO761单药或联合用药的推荐剂量（RD）。HRO761单药的剂量探索部分包括剂量递增，随后根据需要进行随机剂量优化。

[Translation]

The purpose of this study is to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of HRO761 alone (s.a.) or in combination with the anti-PD-1 antibody tislelizumab or the topoisomerase inhibitor irinotecan. The primary objectives of the dose-finding part are to determine a safe and tolerable dose and dosing schedule and to determine the recommended dose (RD) of HRO761 alone or in combination. The dose-finding part of HRO761 alone includes dose escalation, followed by randomized dose optimization as needed.

Start Date16 Jul 2024

Sponsor / Collaborator

China Novartis Institutes for BioMedical Research Co., Ltd.

[+2]

NCT05838768 / RecruitingPhase 1

An Open-label, Multi-center Phase I/Ib Dose Finding and Expansion Study of HRO761 as Single Agent and in Combinations in Patients With Microsatellite Instability-High or Mismatch Repair Deficient Advanced Solid Tumors.

The main purpose of the study is to evaluate the safety and tolerability of HRO761 and identify the recommended dose(s), i.e., the optimal safe and active dose of HRO761 alone or in combination with pembrolizumab or irinotecan that can be given to patients who have cancers with specific molecular alterations called MSIhi (Microsatellite Instability-high) or dMMR (Mismatch Repair Deficient) that might work best to treat these specific cancer types and to understand how well HRO761 is able to treat those cancers.

Start Date27 Jun 2023

Sponsor / Collaborator

Novartis Pharmaceuticals Corp.

100 Clinical Results associated with HRO-761

100 Translational Medicine associated with HRO-761

100 Patents (Medical) associated with HRO-761

Literatures (Medical) associated with HRO-761

09 May 2024·Nature

Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers

Article

Author: Kerr, Grainne ; Hamon, Jacques ; Schrapp, Maxime ; Zécri, Frédéric ; Gavioli, Elena ; Jaco, Isabel ; Dourdoigne, Marion ; Martus, Hans-Joerg ; Laborde, Laurent ; Andraos-Rey, Rita ; Ferretti, Stephane ; Heuser, Alisa ; Reschke, Markus ; Schaeffer, Fanny ; Strang, Ross ; Hattenberger, Marc ; Bechter, Elisabeth ; Schoepfer, Joseph ; Scheufler, Clemens ; Núñez, Eloísa Jiménez ; Dammassa, Ernesta ; Quadt, Cornelia ; Wartmann, Markus ; Blank, Jutta ; Decker, Andrea ; Romanet, Vincent ; Barbe, Stephanie ; Cortés-Cros, Marta ; Welly, Sarah ; Möbitz, Henrik ; Bordas, Vincent ; Voshol, Hans ; Di Nanni, Noemi ; Hemmerlin, Christelle ; Hinrichs, Jürgen ; de Kanter, Ruben ; Hofmann, Francesco

AbstractThe Werner syndrome RecQ helicase WRN was identified as a synthetic lethal target in cancer cells with microsatellite instability (MSI) by several genetic screens1–6. Despite advances in treatment with immune checkpoint inhibitors7–10, there is an unmet need in the treatment of MSI cancers11–14. Here we report the structural, biochemical, cellular and pharmacological characterization of the clinical-stage WRN helicase inhibitor HRO761, which was identified through an innovative hit-finding and lead-optimization strategy. HRO761 is a potent, selective, allosteric WRN inhibitor that binds at the interface of the D1 and D2 helicase domains, locking WRN in an inactive conformation. Pharmacological inhibition by HRO761 recapitulated the phenotype observed by WRN genetic suppression, leading to DNA damage and inhibition of tumour cell growth selectively in MSI cells in a p53-independent manner. Moreover, HRO761 led to WRN degradation in MSI cells but not in microsatellite-stable cells. Oral treatment with HRO761 resulted in dose-dependent in vivo DNA damage induction and tumour growth inhibition in MSI cell- and patient-derived xenograft models. These findings represent preclinical pharmacological validation of WRN as a therapeutic target in MSI cancers. A clinical trial with HRO761 (NCT05838768) is ongoing to assess the safety, tolerability and preliminary anti-tumour activity in patients with MSI colorectal cancer and other MSI solid tumours.

100 Deals associated with HRO-761

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Microsatellite Instability-high Solid Tumors	Phase 1	TW	Novartis Pharmaceuticals Corp.	27 Jun 2023
Microsatellite Instability-high Solid Tumors	Phase 1	US	Novartis Pharmaceuticals Corp.	27 Jun 2023
Microsatellite Instability-high Solid Tumors	Phase 1	CN	Novartis Pharmaceuticals Corp.	27 Jun 2023
Microsatellite Instability-high Solid Tumors	Phase 1	NO	Novartis Pharmaceuticals Corp.	27 Jun 2023
Microsatellite Instability-high Solid Tumors	Phase 1	IT	Novartis Pharmaceuticals Corp.	27 Jun 2023
Microsatellite Instability-high Solid Tumors	Phase 1	SG	Novartis Pharma AG	27 Jun 2023
Microsatellite Instability-high Solid Tumors	Phase 1	SE	Novartis Pharmaceuticals Corp.	27 Jun 2023
Microsatellite Instability-high Solid Tumors	Phase 1	SG	Novartis Pharmaceuticals Corp.	27 Jun 2023
Microsatellite Instability-high Solid Tumors	Phase 1	ES	Novartis Pharmaceuticals Corp.	27 Jun 2023
Microsatellite Instability-high Solid Tumors	Phase 1	JP	China Novartis Institutes for BioMedical Research Co., Ltd.	27 Jun 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis